Novartis AG (NYSE: NVS) announces that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. Novartis completed the acquisition of Avidity through the merger of its indirect wholly owned subsidiary, Ajax Acquisition Sub, Inc., with and into Avidity. As a result of the merger, holders of Avidity common stock became entitled to receive USD 72.00 per share in cash, valuing the company at approximately USD 12bn on a fully diluted basis and representing an enterprise value of approximately USD 11bn.
Read the full article: Novartis Successfully Completes Acquisition of Avidity Biosciences //
Source: https://www.globenewswire.com/news-release/2026/02/27/3246557/0/en/Novartis-successfully-completes-acquisition-of-Avidity-Biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xRNA-strategy.html